Medical Oncology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK.
Gynecol Oncol. 2011 Jun 1;121(3):625-36. doi: 10.1016/j.ygyno.2010.12.351. Epub 2011 Feb 25.
Malignant ovarian germ cell tumours (MOGCT) are rare cancers of young women. Limited prospective trials exist from which evidence-based management can be developed. This review summarizes the available literature concerning MOGT in order to provide the clinician with information relevant to their multidisciplinary management.
MEDLINE was searched between 1966 and 2010 for all publications in English where the studied population included women diagnosed with malignant ovarian germ cell tumours.
The majority of patients can be cured with fertility-preserving surgery with or without combination chemotherapy. Long term survival approaches 100% in early stage disease and is approximately 75% in advanced stage disease. Most studies suggest that the treatment has little, if any, effect on future fertility and limited data suggest that there is no adverse effect on the future quality of life.
MOGCTs are rare tumours of young women the majority of which can be successfully treated with fertility-preserving surgery with or without chemotherapy with preservation of reproductive function. Minimisation of chemotherapy in good prognostic groups and improved treatment in resistant and relapsed MOGCT are important goals for the future. Further studies are needed to quantify the late adverse effects of treatment in long term survivors.
卵巢恶性生殖细胞肿瘤(MOGCT)是一种罕见的年轻女性癌症。目前仅有有限的前瞻性试验,无法据此制定循证治疗方案。本综述旨在对现有关于 MOCT 的文献进行总结,为多学科治疗提供相关信息。
检索 1966 年至 2010 年间发表的所有英文文献,研究对象为诊断为卵巢恶性生殖细胞肿瘤的女性。
大多数患者可通过保留生育能力的手术联合或不联合化疗治愈。早期疾病的长期生存率接近 100%,晚期疾病的生存率约为 75%。大多数研究表明,治疗对未来生育能力几乎没有影响,有限的数据表明,治疗对未来生活质量没有不利影响。
MOGCT 是一种罕见的年轻女性肿瘤,大多数患者可通过保留生育能力的手术联合或不联合化疗成功治疗,保留生殖功能。减少预后良好患者的化疗剂量,改善耐药和复发 MOGCT 的治疗效果是未来的重要目标。需要进一步研究以量化长期生存者治疗的晚期不良影响。